Which has better valuation & earnings, AVIR or VANI?

Vivani Medical is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atea Pharmaceuticals N/A N/A -$158.35M -$2.08 N/A Vivani Medical N/A N/A -$26.61M -$0.35 N/A

Is AVIR or VANI more profitable?

Atea Pharmaceuticals' return on equity of -64.25% beat Vivani Medical's return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -64.25% -57.12% Vivani Medical N/A -191.05% -70.91%

Do analysts prefer VANI or CGC?

Vivani Medical presently has a consensus price target of $3.75, suggesting a potential upside of 204.88%. Given Vivani Medical's stronger consensus rating and higher possible upside, research analysts plainly believe Vivani Medical is more favorable than Canopy Growth. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivani Medical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Canopy Growth 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has preferable earnings and valuation, TTRX or VANI?

Turn Therapeutics is trading at a lower price-to-earnings ratio than Vivani Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Turn Therapeutics N/A N/A -$3.19M -$0.29 N/A Vivani Medical N/A N/A -$26.61M -$0.35 N/A

Is TTRX or VANI more profitable?

Vivani Medical's return on equity of -191.05% beat Turn Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Turn Therapeutics N/A -230.84% -53.19% Vivani Medical N/A -191.05% -70.91%

Vivani Medical (VANI) Competitors

$1.23 -0.04 (-3.15%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$1.25 +0.02 (+1.30%)

As of 04:00 AM Eastern

Compare

VANI vs. COCH, SPRY, AVIR, CGC, and TTRX

Should you buy Vivani Medical stock or one of its competitors? Vivani Medical's main competitors and comparable companies include Envoy Medical (COCH), ARS Pharmaceuticals (SPRY), Atea Pharmaceuticals (AVIR), Canopy Growth (CGC), and Turn Therapeutics (TTRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Vivani Medical compare to Envoy Medical?

Vivani Medical (NASDAQ:VANI) and Envoy Medical (NASDAQ:COCH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Vivani Medical presently has a consensus target price of $3.75, indicating a potential upside of 204.88%. Envoy Medical has a consensus target price of $2.00, indicating a potential upside of 177.01%. Given Vivani Medical's stronger consensus rating and higher probable upside, equities analysts clearly believe Vivani Medical is more favorable than Envoy Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Envoy Medical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Vivani Medical has a beta of 2.36, meaning that its share price is 136% more volatile than the broader market. Comparatively, Envoy Medical has a beta of 1.91, meaning that its share price is 91% more volatile than the broader market.

Envoy Medical has higher revenue and earnings than Vivani Medical. Vivani Medical is trading at a lower price-to-earnings ratio than Envoy Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivani Medical	N/A	N/A	-$26.61M	-$0.35	N/A
Envoy Medical	$207K	269.25	-$23.76M	-$0.76	N/A

6.8% of Vivani Medical shares are held by institutional investors. Comparatively, 8.6% of Envoy Medical shares are held by institutional investors. 53.3% of Vivani Medical shares are held by insiders. Comparatively, 7.2% of Envoy Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Vivani Medical's average media sentiment score of 0.00 equaled Envoy Medical'saverage media sentiment score.

Company	Overall Sentiment
Vivani Medical	Neutral
Envoy Medical	Neutral

Vivani Medical has a net margin of 0.00% compared to Envoy Medical's net margin of -11,304.83%. Envoy Medical's return on equity of 0.00% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivani Medical	N/A	-191.05%	-70.91%
Envoy Medical	-11,304.83%	N/A	-144.13%

Summary

Vivani Medical beats Envoy Medical on 8 of the 13 factors compared between the two stocks.

How does Vivani Medical compare to ARS Pharmaceuticals?

Vivani Medical (NASDAQ:VANI) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

Vivani Medical has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -184.24%. Vivani Medical's return on equity of -191.05% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivani Medical	N/A	-191.05%	-70.91%
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%

Vivani Medical presently has a consensus target price of $3.75, indicating a potential upside of 204.88%. ARS Pharmaceuticals has a consensus target price of $26.40, indicating a potential upside of 531.58%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Vivani Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

6.8% of Vivani Medical shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 53.3% of Vivani Medical shares are held by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Vivani Medical has higher earnings, but lower revenue than ARS Pharmaceuticals. Vivani Medical is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivani Medical	N/A	N/A	-$26.61M	-$0.35	N/A
ARS Pharmaceuticals	$84.28M	4.93	-$171.30M	-$2.18	N/A

Vivani Medical has a beta of 2.36, indicating that its stock price is 136% more volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

In the previous week, ARS Pharmaceuticals had 21 more articles in the media than Vivani Medical. MarketBeat recorded 21 mentions for ARS Pharmaceuticals and 0 mentions for Vivani Medical. ARS Pharmaceuticals' average media sentiment score of 0.12 beat Vivani Medical's score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Vivani Medical	Neutral
ARS Pharmaceuticals	Neutral

Summary

ARS Pharmaceuticals beats Vivani Medical on 9 of the 15 factors compared between the two stocks.

How does Vivani Medical compare to Atea Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and Vivani Medical (NASDAQ:VANI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Atea Pharmaceuticals' return on equity of -64.25% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-64.25%	-57.12%
Vivani Medical	N/A	-191.05%	-70.91%

Vivani Medical is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A
Vivani Medical	N/A	N/A	-$26.61M	-$0.35	N/A

Atea Pharmaceuticals has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market. Comparatively, Vivani Medical has a beta of 2.36, suggesting that its stock price is 136% more volatile than the broader market.

86.7% of Atea Pharmaceuticals shares are held by institutional investors. Comparatively, 6.8% of Vivani Medical shares are held by institutional investors. 21.6% of Atea Pharmaceuticals shares are held by insiders. Comparatively, 53.3% of Vivani Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Atea Pharmaceuticals currently has a consensus target price of $7.00, indicating a potential upside of 32.58%. Vivani Medical has a consensus target price of $3.75, indicating a potential upside of 204.88%. Given Vivani Medical's higher possible upside, analysts plainly believe Vivani Medical is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Atea Pharmaceuticals' average media sentiment score of 0.00 equaled Vivani Medical'saverage media sentiment score.

Company	Overall Sentiment
Atea Pharmaceuticals	Neutral
Vivani Medical	Neutral

Summary

Atea Pharmaceuticals and Vivani Medical tied by winning 6 of the 12 factors compared between the two stocks.

How does Vivani Medical compare to Canopy Growth?

Vivani Medical (NASDAQ:VANI) and Canopy Growth (NASDAQ:CGC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

Vivani Medical has higher earnings, but lower revenue than Canopy Growth. Vivani Medical is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivani Medical	N/A	N/A	-$26.61M	-$0.35	N/A
Canopy Growth	$293.63M	1.43	-$190.29M	-$0.45	N/A

In the previous week, Canopy Growth had 22 more articles in the media than Vivani Medical. MarketBeat recorded 22 mentions for Canopy Growth and 0 mentions for Vivani Medical. Canopy Growth's average media sentiment score of 1.09 beat Vivani Medical's score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media.

Company	Overall Sentiment
Vivani Medical	Neutral
Canopy Growth	Positive

Vivani Medical presently has a consensus price target of $3.75, suggesting a potential upside of 204.88%. Given Vivani Medical's stronger consensus rating and higher possible upside, research analysts plainly believe Vivani Medical is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Canopy Growth	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Vivani Medical has a net margin of 0.00% compared to Canopy Growth's net margin of -65.33%. Canopy Growth's return on equity of -21.91% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivani Medical	N/A	-191.05%	-70.91%
Canopy Growth	-65.33%	-21.91%	-14.34%

Vivani Medical has a beta of 2.36, meaning that its share price is 136% more volatile than the broader market. Comparatively, Canopy Growth has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

6.8% of Vivani Medical shares are owned by institutional investors. Comparatively, 3.3% of Canopy Growth shares are owned by institutional investors. 53.3% of Vivani Medical shares are owned by insiders. Comparatively, 0.4% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Vivani Medical beats Canopy Growth on 8 of the 14 factors compared between the two stocks.

How does Vivani Medical compare to Turn Therapeutics?

Turn Therapeutics (NASDAQ:TTRX) and Vivani Medical (NASDAQ:VANI) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

Vivani Medical's return on equity of -191.05% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	-230.84%	-53.19%
Vivani Medical	N/A	-191.05%	-70.91%

Turn Therapeutics currently has a consensus target price of $9.00, suggesting a potential downside of 33.38%. Vivani Medical has a consensus target price of $3.75, suggesting a potential upside of 204.88%. Given Vivani Medical's stronger consensus rating and higher probable upside, analysts plainly believe Vivani Medical is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Turn Therapeutics is trading at a lower price-to-earnings ratio than Vivani Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A
Vivani Medical	N/A	N/A	-$26.61M	-$0.35	N/A

In the previous week, Turn Therapeutics had 2 more articles in the media than Vivani Medical. MarketBeat recorded 2 mentions for Turn Therapeutics and 0 mentions for Vivani Medical. Vivani Medical's average media sentiment score of 0.00 beat Turn Therapeutics' score of -0.17 indicating that Vivani Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Turn Therapeutics	Neutral
Vivani Medical	Neutral

6.8% of Vivani Medical shares are held by institutional investors. 53.3% of Vivani Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Vivani Medical beats Turn Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Vivani Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VANI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VANI vs. The Competition

Export

Metric	Vivani Medical	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$114.56M	$12.60B	$7.31B	$13.29B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	-3.51	792.28	274.02	25.69
Price / Sales	N/A	860.20	633.28	76.04
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	6.15	10.62	10.44	6.32
Net Income	-$26.61M	$2.81B	$3.49B	$359.73M
7 Day Performance	1.65%	-0.08%	-0.66%	0.17%
1 Month Performance	-10.87%	-1.31%	-3.16%	-3.27%
1 Year Performance	-16.33%	2.91%	15.15%	5.58%

Vivani Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VANI Vivani Medical	2.4858 of 5 stars	$1.23 -3.1%	$3.75 +204.9%	-18.0%	$114.56M	N/A	N/A	36
COCH Envoy Medical	1.8666 of 5 stars	$0.68 -4.2%	$2.00 +194.0%	-15.1%	$54.82M	$240K	N/A	47	High Trading Volume
SPRY ARS Pharmaceuticals	1.7375 of 5 stars	$4.15 -0.2%	$26.40 +536.1%	-57.9%	$414.20M	$84.28M	N/A	200	Trending News
AVIR Atea Pharmaceuticals	1.7434 of 5 stars	$5.26 +2.1%	$7.00 +33.1%	+82.1%	$413.06M	N/A	N/A	55
CGC Canopy Growth	1.0689 of 5 stars	$0.94 +2.6%	N/A	-28.6%	$411.38M	$293.63M	N/A	1,128	Trending News Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VANI) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vivani Medical (VANI) Competitors

VANI vs. COCH, SPRY, AVIR, CGC, and TTRX

How does Vivani Medical compare to Envoy Medical?

Summary

How does Vivani Medical compare to ARS Pharmaceuticals?

Summary

How does Vivani Medical compare to Atea Pharmaceuticals?

Summary

How does Vivani Medical compare to Canopy Growth?

Summary

How does Vivani Medical compare to Turn Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VANI vs. The Competition

Vivani Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vivani Medical (VANI) Competitors

VANI vs. COCH, SPRY, AVIR, CGC, and TTRX

How does Vivani Medical compare to Envoy Medical?

Do analysts recommend VANI or COCH?

Which has more risk & volatility, VANI or COCH?

Which has preferable valuation and earnings, VANI or COCH?

Do insiders and institutionals believe in VANI or COCH?

Does the media prefer VANI or COCH?

Is VANI or COCH more profitable?

Summary

How does Vivani Medical compare to ARS Pharmaceuticals?

Is VANI or SPRY more profitable?

Do analysts prefer VANI or SPRY?

Do institutionals and insiders believe in VANI or SPRY?

Which has better earnings and valuation, VANI or SPRY?

Which has more volatility and risk, VANI or SPRY?

Does the media prefer VANI or SPRY?

Summary

How does Vivani Medical compare to Atea Pharmaceuticals?

Is AVIR or VANI more profitable?

Which has better valuation & earnings, AVIR or VANI?

Which has more risk and volatility, AVIR or VANI?

Do insiders & institutionals believe in AVIR or VANI?

Do analysts prefer AVIR or VANI?

Does the media refer more to AVIR or VANI?

Summary

How does Vivani Medical compare to Canopy Growth?

Which has higher earnings & valuation, VANI or CGC?

Does the media refer more to VANI or CGC?

Do analysts prefer VANI or CGC?

Is VANI or CGC more profitable?

Which has more risk & volatility, VANI or CGC?

Do insiders and institutionals hold more shares of VANI or CGC?

Summary

How does Vivani Medical compare to Turn Therapeutics?

Is TTRX or VANI more profitable?

Do analysts prefer TTRX or VANI?

Which has preferable earnings and valuation, TTRX or VANI?

Does the media prefer TTRX or VANI?

Do insiders and institutionals have more ownership in TTRX or VANI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VANI vs. The Competition

Vivani Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools